Skip to main content
Tech.euFundingExplorerBeta

Kupando

Germany-based biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases

Kupando has raised €23M across 2 funding rounds from 7 investors, most recently a Series A round in Mar 2026. Based in Berlin, Germany; active in Healthtech. Data as of 28 Oct 2026.

Total raised
€23M
€23,000,000
Funding rounds
2
Investors
7
distinct backers
Active since
2022-09
latest 2026-03

Funding by year

EUR raised per year · 2026 YTD
Kupando — funding by year — interactive chart.
Data table
Kupando — funding by year
2022€13M
2026€10M

Signals

High confidence
Raise-next likelihood35
base rate 44% for Series A
  • ▼ Raised very recently
  • ▼ Down/flat last round
Exit likelihood18
base rate 11% (2+ rounds)
  • ▲ Recent equity round, but funding momentum is down (may be rescue financing)

Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.

Similar companies

same sector or country

Global coverage: FundingData